Publications by authors named "Liting Xue"

Claim this Profile
H
High intratumoral heterogeneity in clear cell renal cell carcinoma is associated with reduced immune response and survival.
Qizhou Yang, Yuying Han, Xu Liu, Liting Xue, Zhengguo Ji

Transl Androl Urol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-801-exposure induces increased translation efficiency and mRNA hyperacetylation of in the mouse prefrontal cortex.
Liting Xue, Jialu Zhao, Xu Liu, Tian Zhao, Ying Zhang

Epigenetics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the -adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors.
Zhiyong Yu, Yi Kuang, Liting Xue, Xuan Ma, Tingting Li, Grace Xue

MedComm (2020)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research.
Wenjing Li, Chunlei Xia, Kun Wang, Liting Xue, Yan Wang

Int Immunopharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
Feng Zhou, Guimei Yang, Liting Xue, Yajing Liu, Yao Guo

Breast Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents.
Leilei Guo, Xiaokang Qin, Liting Xue, Janine Y Yang, Yumei Zhang

Front Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors.
Peng Gu, Liting Xue, Chunyan Zhao, Wenjing Li, Zhen Jiang

Front Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of transcriptome analysis methods with reference genome.
Xu Liu, Jialu Zhao, Liting Xue, Tian Zhao, Wei Ding

BMC Genomics· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.
Liting Xue, Xingyuan Gao, Haoyu Zhang, Jianxing Tang, Qian Wang

BMC Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
Anuradha Illendula, John A Pulikkan, Hongliang Zong, Jolanta Grembecka, Liting Xue

Science· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Leyuan Ma, Yi Shan, Robert Bai, Liting Xue, Christopher A Eide

Sci Transl Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Liting Xue, John A Pulikkan, Peter J M Valk, Lucio H Castilla

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
John Anto Pulikkan, Dmitri Madera, Liting Xue, Paul Bradley, Sean Francis Landrette

Blood· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Map4k4 negatively regulates peroxisome proliferator-activated receptor (PPAR) gamma protein translation by suppressing the mammalian target of rapamycin (mTOR) signaling pathway in cultured adipocytes.
Kalyani V P Guntur, Adilson Guilherme, Liting Xue, Anil Chawla, Michael P Czech

J Biol Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis